Abstract:Objective To investigate whether pantoprazole (PPZ), a proton pump inhibitor,could reverse the transmember pH gradient by inhibiting vacuolar H+-ATPase so as to increase the sensitivity of human gastric adenocarcinoma cell line SGC7901 to antitumor drugs and to evaluate the optimal time of drug administration, dosage of PPZ and the possible mechanism. Methods Western blotting and immunofluorescent staining were used to determine the expression and intracellular distribution of vacuolar H+-ATPase in human gastric adenocarcinoma cell line SGC7901 with or without PPZ pretreatment. 2', 7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester (BCECF-AM) fluorescent probe was used to measure the intracellular pH value of human gastric adenocarcinoma cell line SGC7901 which pretreated with different dose and time of PPI. Methyl thiazolyl tetrazolium (MTT) assay and annexin V-fluorescent isothiocyanate-propidium iodide double staining were performed to evaluate the cytotoxic effects and apoptosis of cells treated with antitumor drugs combined with PPZ. Adriamycin (ADR) was used as probe to estimate drug accumulation and retention with PPZ pretreatment. Results After 24 hours, the expression of vacuolar H+-ATPase in cells pretreated with PPZ of 10 μg/ml (1.19±0.03) or 100 μg/ml (0. 70±0.03) was significantly lower than that in blank control (1.53±0. 05), but this expression was increased by pretreatment with PPZ of 1 μg/ml (2.29 +0.06, P<0.05). The inhibitory effects of PPZ (10 μg/ml) on vacuolar H+-ATPase was observed at 6 hours (0.32±0.02)and 12 hours (0. 13±0.02). And it could alter the intracellular distribution of vacuolar H+-ATPase at 24-hours. The intracellular pH value in cells pretreated with PPZ of 10 μg/ml (7.44±0. 09 ) or 100 μg/ml (7.31 ± 0. 06) was significantly decreased in comparison with untreated cells (7.51±0.05, P< 0. 01). After administration of anti-tumor drugs, the viability in SGC7901 cells pretreated with PPZ for 24 hours (58.71%±1.18 %) was significantly lower than that in cells untreated with PPZ (74. 33% ± 1.77%, P<0.05), while thetotal and early apoptotic rates in former cells(80.81% ±1. 16% and 77.52 %±1.13 %, respectively) were significantly higher than those in later cells (26. 42%±1.19% and 23. 18% ±0.92%,respectively,P < 0. 01). And the ADR releasing index in cells treated with PPZ (20, 50 and 100 μg/ml) for 24 hours was obviously lower than that in the blank control (0. 164±0. 013, 0. 162±0.015, 0. 152±0. 012 vs 0. 277±0. 011, respectively, P<0. 01). Conclusion The sensitivity of human gastric adenocarcinoma cell line to antitumor drugs may be increased by pretreatment with PPZ.

Effect and Mechanism of Pioglitazone on Cell Growth in Human Gastric Cancer Cells

Peroxisome proliferator-activated receptor γ agonist pioglitazone inhibits glioma cell growth mediated by β-catenin

Poster Session AP2: Cell Death and Survival

Pioglitazone, a PPARγ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling

Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells

Peroxisome Proliferator-Activated Receptor-Gamma is Essential in the Pathogenesis of Gastric Carcinoma

[Effects of Peroxisome Proliferator-Activated Receptor-Gamma Ligand Troglitazone on Colon Cancer Cell Growth].

Effect of Silencing PPARγ by RNA Interference on Growth of Human Gastric Carcinoma Cells

Pretreatment with Proton Pump Inhibitor Increases Sensitivity of Human Gastric Adenocarcinoma Cell Line to Antitumor Drugs

Lobeglitazone, A Peroxisome Proliferator-Activated Receptor-Gamma Agonist, Inhibits Papillary Thyroid Cancer Cell Migration and Invasion by Suppressing p38 MAPK Signaling Pathway

Z-Guggulsterone Inhibits Tumor Cell Proliferation, Migration in Vitro and Tumor Growth in Vivo Through PTEN/Akt/COX-2 Signaling Pathway

Investigation of the inhibition effect of 1,2,3,4,6-pentagalloyl-β-D-glucose on gastric cancer cells based on a network pharmacology approach and experimental validation

The Inhibition of the Breast Cancer by PPARγ Agonist Pioglitazone Through JAK2/STAT3 Pathway.

Effects of Polyphyllin I on Growth Inhibition of Human Non-Small Lung Cancer Cells and in Xenograft

Troglitazone Inhibits Cell Proliferation by Attenuation of Epidermal Growth Factor Receptor Signaling Independent of Peroxisome Proliferator-Activated Receptor Γ

PPARγ Ligands Inhibit Cholangiocarcinoma Cell Growth Through P53-Dependent GADD45 and P21waf1/cip1 Pathway

PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway.

Peroxisome Proliferator-Activated Receptor Γ Ligands Induce Cell Cycle Arrest and Apoptosis in Human Renal Carcinoma Cell Lines

Study on Action Mechanisms for the Effect of Pseudolaric Acid B in Inducing Apoptosis of Human Gastric Carcinoma Cell Line AGS

Pioglitazone, a peroxisome proliferator‐activated receptor γ agonist, induces cell death and inhibits the proliferation of hypoxic HepG2 cells by promoting excessive production of reactive oxygen species

Dihydromyricetin Induces Cell Apoptosis Via A P53-Related Pathway in Ags Human Gastric Cancer Cells